Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat in Japanese subjects with anemia secondary to DD-CKD
NCT03054350Phase 2Completed
- Sponsor
- Akebia Therapeutics
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vadadustat in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by Akebia Therapeutics. Primary endpoint: Mean Change in Hemoglobin (Hb) Levels From Pre-treatment to the End of the Primary Efficacy Period at 6 weeks. Started Dec 2016; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03054350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03054350.